Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pravastatin adjunctive therapy in TB
NCT03882177Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pravastatin in pulmonary tuberculosis (TB) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Frequency of Grade 3 or Higher Adverse Events at Day 30. Started Feb 2020; status: completed.
02
Drugs
pravastatin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT03882177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03882177.